Icosavax — Technical Presentation (June 2022)
27 slides from Icosavax's technical presentation, Jun 28, 2022
Slide 1: IVX-121 Phase 1/1b Topline Data
IVX-121 Phase 1/1b Topline Data June 28, 2022 Exhibit 99.2
Slide 2: Forward looking statements
Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include but are not limited to: the potential for the co
Slide 3: Agenda
Agenda Introduction and Key Takeaways Adam Simpson Chief Executive Officer Topline Data Niranjan Kanesa-thasan, M.D. Chief Medical Officer Wrap-up and Q&A Adam Simpson Chief Executive Officer Niranjan Kanesa-thasan, M.D. Chief Medical Officer Tom Russo Chief Financial Officer
Slide 4: Positive IVX-121 Phase 1/1b topline interim results
Positive IVX-121 Phase 1/1b topline interim results Initial indication of the company’s differentiated VLP platform technology High RSV-A and RSV-B neutralizing antibody titers seen even at lowest dose tested Positive topline data from the Phase 1/1b trial of IVX-121 suggest a competitive initial pr
Slide 5: VLPs may offer one or more of these potential benefits
VLPs may offer one or more of these potential benefits Magnitude of response When compared to existing modalities, WE BELIEVE OUR VLP TECHNOLOGY HAS THE POTENTIAL TO IMPROVE UPON: Breadth of coverage Durability to counter immunosenescence that can occur in the elderly greater degree of protection ag
Slide 6: Unlike soluble antigens, VLPs mimic the structure of real viruses
Unlike soluble antigens, VLPs mimic the structure of real viruses Natural virus Soluble antigen VLP-based antigen Traditionally manufactured or mRNA-derived
Slide 7: Our VLPs are produced via a proprietary, 2-component, computationally-designed system
Our VLPs are produced via a proprietary, 2-component, computationally-designed system IVX-121 IVX-241 FLU IVX-411 hMPV RSV SARS-CoV-2 FLU Trimeric protein genetically fused to target antigen Antigen properly folds to display neutralizing epitopes before assembly into VLP New antigen design capabilit
Slide 8: IVX-121 for RSV: Prefusion RSV-F protein may lead to higher neutralizing antibody titers
Graham et al 2015; Ruckwardt et al 2021 IVX-121 for RSV: Prefusion RSV-F protein may lead to higher neutralizing antibody titers Proof of concept Subunit (Ph1) Subunit Recombinant vector or mRNA VLP Companies & Technologies: mRNA DS-Cav1 Adult Neutralizing Titer GMFR ~7-10x Postfusion protein subuni
Slide 9: IVX-121 for RSV: Ph 1/1b trial initiated September 2021
IVX-121 for RSV: Ph 1/1b trial initiated September 2021 Phase 1b revaccination Subset of Ph 1b OA cohort 12 months follow-up Revaccination at 12 months after initial Ph 1b dose Following the Phase 1/1b trial, we plan to combine IVX-121 with IVX-241 (our hMPV candidate) for further clinical developme
Slide 10: IVX-121 Phase 1/1b Topline Data
IVX-121 Phase 1/1b Topline Data
Slide 11: Study Design: Phase 1/1b randomized, observer-blinded, placebo-controlled study
Study Design: Phase 1/1b randomized, observer-blinded, placebo-controlled study to evaluate IVX-121 administration in young and older adult subjects Young Adult Subjects (ages 18-45) n=90 PH1 Older Adult Subjects (ages 60-75) n=130 PH1b alum: 500 µg/mL aluminum hydroxide Placebo 25, 75, or 250 µg No
Slide 12: Summary of safety data
Summary of safety data No SAEs, AEs of special interest (AESIs) or AEs leading to study withdrawal IVX-121 n (%) Placebo n (%) IVX-121 n (%) Placebo n (%) Any serious adverse event (AE) 0 0 0 0 Any AE of special interest 0 0 0 0 Any AE leading to death or study discontinuation 0 0 0 0 Any grade 4 (l
Slide 13: Solicited adverse events within 7 days of single dose
No Adjuvant 25 µg 75 µg 250 µg + alum 25 µg 75 µg 250 µg Placebo Placebo Solicited adverse events within 7 days of single dose, maximal severity Unadjuvanted IVX-121 reactogenicity is mild in older adults with similar tolerability to placebo alum: 500 µg/mL aluminum hydroxide Older Adult Subjects (a
Slide 14: Topline immunogenicity data: RSV-A nAb (unadjuvanted)
Topline immunogenicity data: RSV-A nAb (unadjuvanted) GMT expressed in IU/mL – Viroclinics Live nAb Assay Geometric mean titers (in IU/mL) of unadjuvanted IVX-121 are comparable in young and older adults GMT: Geometric mean titer; LLoQ = 9.9; GMFR: Geometric Mean Fold Rise (Day 28) from Baseline. As
Slide 15: Topline immunogenicity data: RSV-A nAb (unadjuvanted vs. adjuvanted)
Topline immunogenicity data: RSV-A nAb (unadjuvanted vs. adjuvanted) GMT expressed in IU/mL – Viroclinics Live nAb Assay Alum adjuvant had no beneficial effect in young and older adults GMT: Geometric Mean Titer. LLoQ = 9.9. alum: 500 µg/mL aluminum hydroxide. Assays conducted by Viroclinics GMT (95
Slide 16: Clinical study met primary safety and immunogenicity objectives
Clinical study met primary safety and immunogenicity objectives Generally well tolerated with no serious or dose limiting adverse events in adults, including older adults Mild reactogenicity associated with unadjuvanted IVX-121 in older adults Systemic adverse events comparable to placebo for older
Slide 17: Wrap-up
e- 1COSAVAX Wrap-up
Slide 18: Favorable IVX-121 tolerability data in Phase 1/1b study
Favorable IVX-121 tolerability data in Phase 1/1b study RSV vaccines – OA Shingles vaccine Quadrivalent influenza vaccines – OA1 RSVpreF3 (w/ AS01) Ad26.RSV. preF + preF RSVpreF2 mRNA-1345 Shingrix (w/ AS01) Fluzone Flublok Afluria mRNA-10103 IVX-121 25-250 µg - OA N=111 (GSK) (Janssen) (Pfizer) (Mo
Slide 19: IVX-121 elicits high RSV-A NAb titers relative to DS-Cav1 antigen
At comparable or lower antigen dose equivalents, IVX-121 elicits high RSV-A NAb titers relative to those previously shown for DS-Cav1 antigen DS-Cav1 soluble protein (NIH)2 YA immunogenicity, ~1 month post dose (unadjuvanted): RSV-A neutralization assays (IU/mL)1 IVX-121 VLP YA (18-50) YA (18-45) **
Slide 20: IVX-121 neutralizing antibody titers in estimated range of a leading RSV candidate
IVX-121 neutralizing antibody titers are in the estimated range of a leading RSV candidate in Phase 3 for older adults RSVpreF soluble protein (Pfizer; estimated titers) IVX-121 VLP (Older Adults) Ph 2 Young adults (YA) human challenge3 Ph 1/2 Older Adults2 dose recently demonstrated ~87% efficacy i
Slide 21: VLPs may offer one or more of these potential benefits
VLPs may offer one or more of these potential benefits Magnitude of response When compared to existing modalities, WE BELIEVE OUR VLP TECHNOLOGY HAS THE POTENTIAL TO IMPROVE UPON: Breadth of coverage Durability to counter immunosenescence that can occur in the elderly greater degree of protection ag
Slide 22: Our first combination vaccine candidate—IVX-A12—targets both RSV and hMPV
Our first combination vaccine candidate—IVX-A12—targets both RSV and hMPV Found in 8% of US adults hospitalized for pneumonia where pathogen detected 16% likelihood of ICU admission, 5% likelihood of death Symptoms: Cough, fatigue, dyspnea, congestion, wheezing, fever RSV Found in 11% of US adults h
Slide 23: Q&A
e- 1COSAVAX Q&A
Slide 24: Appendix
e- 1COSAVAX Appendix
Slide 25: Demographics of trial participants
Demographics of trial participants Young Adult Subjects (ages 18-45) n=90 PH1 Older Adult Subjects (ages 60-75) n=130 PH1b IVX-121 N=84 Placebo N=6 Gender Male (%) 31.0 66.7 Female (%) 69.0 33.3 Age Average Age (min, max) 30.1 (18, 44) 33.3 (21, 41) Race White or Caucasian (%) 97.6 100 BMI (kg/m2) M
Slide 26: GMT ranges for RSV-A and RSV-B in older adults
GMT ranges for RSV-A and RSV-B in older adults Older Adult Subjects (ages 60-75) PH1b RSV-A 25 µg 75 µg 250 µg GMT (95% CI) Day 28 Results (Unadjuvanted) N= 19 18 18 Pattern of RSV-B responses show immunogenicity even at lowest dosage level and comparable ranges to those of RSV-A RSV-B Day 28 Result
Slide 27: Icosavax is the only company pursuing RSV and hMPV with the VLP modality
Icosavax is the only company pursuing RSV and hMPV with the VLP modality PRECLINICAL PHASE 1 PHASE 2 PHASE 3 VLP Subunit / Soluble Antigen Recombinant Vector GSK Prefusion RSV-F + AS01 Pfizer Prefusion RSV-F Janssen Adenovirus + soluble RSV-F Bavarian Nordic MVA RSV-F Live-Attenuated Meissa RSV Most